A ratiometric imaging platform to advance COVID-19 counter measures

用于推进 COVID-19 应对措施的比例成像平台

• 批准号: 552990-2020
• 负责人: Ryan, Scott
• 金额: $ 3.64万
• 依托单位: University of Guelph
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=703927
• 关键词: ratiometric; imaging; platform; advance; COVID

COVID-19 is a severe acute respiratory syndrome (SARS) caused by infection of lung epithelial cells with the SARS coronavirus 2 (SARS-CoV-2). CoV replication requires the acidic environment of a cell compartment called the lysosome. As such, monitoring the lysosome accumulation may represent a means of studying viral replication and monitoring viral load. We propose to repurpose our considerable expertise and industry partnerships that were developed while studying lysosomes in neurodegenerative disease to develop, optimize and validate a fast, low-cost, high-throughput approach to measuring CoV accumulation and replication in the lysosomes of lung cells. The primary goals of this project are therefore, 1) to develop and optimize a microscopy-based measurement of SARS-CoV-2 levels in the lysosome 2) to develop a module for a widely used microscopy software that will enable fast, accurate measurement of SARS-CoV-2 replication, and 3) to validate that this new tool permits the study of CoV replication. To do this, we have partnered with Quorum Technologies, a Canadian owned enterprise located in Guelph, Ontario that develops microscopes and microscopy-software for the life sciences. The ratiometric imaging software module we develop will also be used to conduct proof-of-principle tests that will determine whether the system accurately measures SARS-CoV-2 replication. Given diagnostic and prognostic measures of viral load in COVID-19 patients are sorely lacking and urgently needed, the proposed work represents an important step towards accelerating COVID-19 countermeasures.

COVID-19是一种严重急性呼吸道综合征（SARS），由SARS冠状病毒2（SARS-CoV-2）感染肺上皮细胞引起。CoV的复制需要一个叫做溶酶体的细胞区室的酸性环境。因此，监测溶酶体积累可以代表研究病毒复制和监测病毒载量的手段。 我们建议重新利用我们在研究神经退行性疾病中的溶酶体时开发的大量专业知识和行业合作伙伴关系，以开发，优化和验证快速，低成本，高通量的方法来测量肺细胞溶酶体中的CoV积累和复制。因此，该项目的主要目标是：1）开发和优化基于显微镜的溶酶体中SARS-CoV-2水平的测量; 2）为广泛使用的显微镜软件开发一个模块，该模块将能够快速，准确地测量SARS-CoV-2复制; 3）验证这种新工具允许研究CoV复制。为此，我们与Quorum Technologies合作，Quorum Technologies是一家位于安大略圭尔夫的加拿大独资企业，为生命科学开发显微镜和显微镜软件。我们开发的比率成像软件模块也将用于进行原理验证测试，以确定该系统是否准确测量SARS-CoV-2复制。鉴于COVID-19患者病毒载量的诊断和预后措施严重缺乏且迫切需要，拟议的工作代表了加速COVID-19对策的重要一步。